Industry Reports
Bayer Second quarter of 2016: Bayer raises sales and earnings:
Group sales increase by 2.3 percent (Fx & portfolio adj.) to EUR 11,833 million / Pharmaceuticals continues strong growth trend / Consumer Health increases sales / Crop Science business holds steady in a continuingly difficult market environment / EBITDA...
Industry Reports
Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics
Pfizer Inc announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C., focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions...
Industry Reports
Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results
Momenta Pharmaceuticals, Inc reported its financial results for the second quarter ended June 30, 2016.For the second quarter of 2016, the Company reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandoz's sale of Glatopa®...
Industry Reports
Boehringer Ingelheim: Growth in all core businesses
Boehringer Ingelheim reported currency-adjusted growth in all its core businesses in the first half of 2016. At the same time, the research-driven pharmaceutical company achieved key strategic milestones by signing contracts to exchange businesses with Sanofi and completing the...
Industry Reports
GSK announced the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance Group sales £6.5 billion, +4% CER, with growth across all three businesses  -Pharmaceuticals £3.9 billion, +2%; Vaccines £960 million, +11%; Consumer Healthcare, £1.7 billion, +7%...
Industry Reports
Merck Announces Fourth-Quarter 2016 Dividend
Merck known as MSD outside the United States and Canada announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of 2016. Payment will be...
Industry Reports
Novartis Q2 results enhance future growth prospects with eight significant regulatory milestones
Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (USD 260 million) grew strongly driven by its three approved indications Core operating income declined (-4% cc) due...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.